Anocca has announced the appointment of Jacob Michlewicz as Chief Financial Officer, effective immediately, and based at the company’s headquarters in Sweden.
“We’re delighted for Jacob to join us as CFO, following swiftly on from our recent Series B financing, which took us to well over $100m (SEK 900 million) raised since our founding. Jacob’s depth and breadth of experience will be a great asset as we methodically move towards our vision of delivering blockbuster franchises of next generation T-cell immunotherapies for the treatment of multiple cancer types,” says Anocca’s CEO and co-founder Reagan Jarvis.
Jacob Michlewicz has over 20 years of experience, including strategy consultancy with McKinsey & Company and managerial positions in Pharmaceutical, BioTech and MedTech industries across Europe and the US. Most recently, he was CFO at Bioservo Technologies AB, a global leader within the active exoskeleton market, listed on the Nasdaq First North Growth Market, where he successfully supported company financing. Jacob received his MBA from the University of Michigan, Ann Arbor, USA.
“Anocca has done exceptionally well as a European biotech to raise capital to fund its leading-edge R&D efforts. The company’s technical platform can touch everything from vaccines to therapeutics. I’m relishing the opportunity to work together with the team to further advance the company as a global scientific and technical leader in the field of TCR-T cell immunotherapy,” says Jacob Michlewicz.
Photo of Jacob Michlewicz